Efficacy and Safety of EGFR-TKIs for Elderly Patients With NSCLC
January 18, 2024
In a new study, researchers investigated the effectiveness and safety of EGFR-tyrosine kinase inhibitors in elderly patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC). continue reading »